Baguio signs deal with AstraZeneca to vaccinate 70 percent of its population | Inquirer News

Baguio signs deal with AstraZeneca to vaccinate 70 percent of its population

/ 11:30 AM January 11, 2021

BAGUIO CITY –– Mayor Benjamin Magalong on Sunday signed a deal with British pharmaceutical AstraZeneca for vaccine doses good for 70 percent of the city’s 350,000 population.

The arrangement was part of a tripartite agreement between the company, the Department of Health, and the National Task Force on Emerging and Re-emerging Disease.


Magalong earlier announced he had negotiated 10,000 doses from a global company and had secured the commitment of local businessmen and the Baguio Chamber of Commerce and Industry for half of the vaccines they would procure for their workforce.

In a statement on Monday, Magalong said the local government had received pledges for 33,000 doses.


He said the city had approached other pharmaceutical companies for additional vaccine supplies.

The city is setting aside P100 million for the vaccine purchase.


For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: AstraZeneca, Baguio City, British pharmaceutical, coronavirus disease, COVID-19, deal, Health, Mayor Benjamin Magalong, Philippine news updates, Vaccines
For feedback, complaints, or inquiries, contact us.

© Copyright 1997-2021 | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.